Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ajovy (fremanezumab-vfrm) is indicated for the preventive treatment of migraine in adults.
• This summary is based on the review of 28 systematic review(s)/meta-analysis(es). ^[1-28]
• Fremanezumab significantly reduced monthly migraine days compared to placebo, with the most effective dose for chronic migraine showing a mean difference of -2.77 days (95% CrI: -3.36 to -2.17).
• The responder rate for patients achieving at least a 50% reduction in mean monthly migraine days was 54%, with a similar rate (57%) for mean monthly headache days.
• Fremanezumab was effective in transitioning patients from medication overuse status, particularly in the triptan group, with a relative risk (RR) of 1.71 (95% CI: 1.53 to 1.91; p < 0.001).
• In comparisons with other treatments, fremanezumab often showed superior effectiveness in reducing monthly migraine days, especially when compared to topiramate and onabotulinumtoxinA, with a higher likelihood of benefit versus harm.
• The majority of study participants were women (85.1%), with only two studies analyzing results by sex and no specific discussion of results for men. Effectiveness was observed in both episodic and chronic migraine patients, with slightly better outcomes in chronic migraine. Fremanezumab was notably effective in reducing medication overuse, particularly in patients with medication overuse or medication overuse headache, with a higher responder rate in the triptan group.